Periodic Reporting for period 1 - SEB (Scalable and Eco-friendly Bioproduction)
Reporting period: 2023-01-01 to 2023-12-31
Founded in 2020, Core Biogenesis is a French biotech startup whose aim is to become a European leader of sustainable bioproduction. Through a patented plant-based production platform, the company unlocks the promises of bioeconomy by allowing large production of pharmaceutical-grade recombinant proteins. The first applications tackled are growth factors and cytokines used in Xeno Free cell culture media for cell and gene therapies manufacturing, which currently represent a considerable bottleneck because of high production costs and insufficient volumes. Other applications fields comprise food biotech, cosmetics, and therapeutics at a later stage. After promising proofs of concept and the setup of an industrial demonstrator in Strasbourg, the company is initiating its scale-up to commercially meet market demand within aggressive timelines.
The ambitious Scalable Ecofriendly Bioproduction (SEB) project supported by the EIC was designed to accelerate the standardization and industrialization of its plant-based GF biomanufacturing platform. This 360° scale-up deals with both upstream (biomass generation : crop growth) and downstream (GF extraction and purification) phases of the production process. Core Biogenesis’ development strategy is based on 4 main objectives:
- To generate and validate transgenic Camelina Sativa strains producing IPSC cell culture specific growth factors
- To optimize greenhouse and open field culture protocols of these strains in order to generate sufficient biomass
- To optimize and validate the extraction, purification and quality control process of the specified growth factors.
- To obtain GMP qualification for the GF for application in clinical & commercial fields, but also food biotech industry or cosmetics in response to market traction.
The ambitious Scalable Ecofriendly Bioproduction (SEB) project supported by the EIC was designed to accelerate the standardization and industrialization of its plant-based GF biomanufacturing platform. This 360° scale-up deals with both upstream (biomass generation : crop growth) and downstream (GF extraction and purification) phases of the production process. Core Biogenesis’ development strategy is based on 4 main objectives:
- To generate and validate transgenic Camelina Sativa strains producing IPSC cell culture specific growth factors
- To optimize greenhouse and open field culture protocols of these strains in order to generate sufficient biomass
- To optimize and validate the extraction, purification and quality control process of the specified growth factors.
- To obtain GMP qualification for the GF for application in clinical & commercial fields, but also food biotech industry or cosmetics in response to market traction.